Friday, February 13, 2026

[NEW FLAVOR] Peanut butter chocolate chip protein crispy treat 🥜🍫

Want BOGO 50% off your first Legion order?

Use the coupon code BOGO50 and immediately get buy one get one 50% off savings on your first Legion order. Shop now.

Don't forget to redeem your Legion points for instant savings.

Your Legion Rewards Points Balance: 0 points (worth $0). Redeem now.

Don't have a Legion account? Create one now and earn points in a number of easy ways and redeem them for exclusive gifts and discounts on everything in our store.

Want free tools for figuring out your calories, macros, body fat level, and more? Click here to check out my fitness tools hub.

To update your email preferences, click here.

To unsubscribe, click here.

Legion Athletics, Inc. 601 Cleveland St. 3rd Floor, Suite 300 Clearwater, FL 33755

Quick Steak + Shrimp Skillet

Hey reader

This is the type of meal we eat in our clean-eating programs!

Quick One-Pan Steak and Shrimp with lots of veggies and Flavor.

When you’re looking for something super satisfying, this high-protein combo of steak & shrimp will definitely do the trick!

This meal comes together quickly and can be enjoyed as is or served over brown rice or quinoa.

We adore one-pot meals!

What about you?!

Easy to make & Fast clean up!

Perfect for meal prep or a quick weeknight dinner idea! Have 20 minutes?

That’s all it takes to pull together a super nutritious and delicious meal!

https://cleanfoodcrush.com/quick-steak-shrimp-skillet/

Share this recipe with your friends and family on social media.

Make today amazing!

❤ Rachel

P.S. The Little Black Dress Project Fall Session starts this Monday, September 16th.

The 6-Week Little Black Dress Project:

✅ is proven to get Insane results.

🤩 Includes 6 weeks of Coaching and Support with CFC's Coaching Team.

Our VIP Members have been using this exact program with great success and rave reviews, so I'm thrilled to offer it to the general public.

Learn more here:

https://cleanfoodlove.com/black-dress/

(If you're a previous CFC member, respond to this email to learn more about our various renewal bonuses and discounts!)

If you wish to stop receiving our emails or change your subscription options, please Manage Your Subscription
CleanFoodCrush, 1192 Draper Parkway Suite #433, Draper, UT 84020, US

Statement on the planned hepatitis B birth dose vaccine trial in Guinea-Bissau

Friday, 13 February 2026

Statement on the planned hepatitis B birth dose vaccine trial in Guinea-Bissau

https://www.who.int/news/item/13-02-2026-statement-on-the-planned-hepatitis-b-birth-dose-vaccine-trial-in-guinea-bissau

The World Health Organization (WHO) underscores that the hepatitis B birth dose vaccine is an effective, and essential public health intervention, with a proven record. It prevents life‑threatening liver disease by stopping mother‑to‑child transmission at birth. It has been used for over three decades, with more than 115 countries including it in their national schedules. Protecting newborns with a timely birth dose not only provides individual benefit but is also central to national and global elimination efforts.

In response to recent questions from the media, WHO would like to state the following:

WHO is aware of the proposed randomized controlled trial (RCT) on the hepatitis B birth dose vaccine in Guinea‑Bissau. Based on questions raised in publicly available information and consultation with relevant experts, WHO has significant concerns regarding the study’s scientific justification, ethical safeguards, and overall alignment with established principles for research involving human participants.

Why withholding the vaccine is unethical

Proven benefit, foreseeable harm: The hepatitis B birth dose vaccine is known to have a proven safety record across decades of use and is effective in preventing 70–95% of cases of mother‑to‑child transmission. A study which provides the hepatitis B birth dose vaccine, a proven lifesaving intervention, but withholds it from some study participants exposes newborns to serious and potentially irreversible harm, including chronic infection, cirrhosis, and liver cancer.
No scientific necessity for a no‑treatment arm: Placebo or no‑treatment vaccine trials are only acceptable when no proven intervention exists or when such a design is indispensable to answer a critical question of efficacy or safety. Neither condition appears to be met based on publicly available descriptions of the study.
Insufficient scientific justification: Publicly available descriptions indicate that the protocol does not question the established efficacy and impact of the birth dose; instead, it posits hypothetical safety outcomes without sufficient credible evidence of a safety signal that would warrant exposing participants to risk.
Biased and low‑utility design: As described publicly, the single‑blind, no‑treatment‑controlled design raises a significant likelihood of substantial risk of bias, limiting interpretability of the study results and their policy relevance.
Exploiting scarcity is not ethical: Resource constraints cannot be used to justify withholding proven care in a research study involving people. Ethical obligations require minimizing risk and ensuring a prospect of benefit for participants. From what is publicly described, the protocol does not appear to ensure even a minimum level of harm reduction and benefit to the study participants (e.g. screening pregnant women and vaccinating newborns exposed to hepatitis B).

In its current form, and based on publicly available information, the trial is inconsistent with established ethical and scientific principles.

WHO is aware that Guinea-Bissau has suspended the study pending further technical reviews. WHO stands ready to support Guinea‑Bissau as it considers its way forward and in accelerating the introduction of the birth dose and strengthening implementation through:

birth‑dose delivery within 24 hours (including strategies for home and facility births);
antenatal screening for hepatitis B surface antigen (HBsAg), linkage to care, and neonatal prophylaxis;
cold‑chain, last‑mile logistics, and midwife/HCW training; and
monitoring of timeliness and coverage, pharmacovigilance, and data use for continuous improvement.

WHO remains committed to working with national authorities, researchers, and partners to ensure that all newborns – in Guinea‑Bissau and worldwide – receive timely, evidence‑based protection against hepatitis B, and that research conducted in this area meets the highest ethical and scientific standards.

Editor’s note

Hepatitis B causes hundreds of thousands of deaths globally each year. Transmission at birth is the most common route to lifelong infection; ~90% of newborns infected during childbirth become chronic carriers at high risk of cirrhosis and liver cancer.

In Guinea‑Bissau, >12% of adults are estimated to be living with chronic hepatitis B (2022), and infection in children under five (~2% in 2020) is far above the global target (≤0.1%). Guinea‑Bissau formally decided in 2024 to add the hepatitis B birth dose to its national schedule, with introduction planned by 2028. This policy decision affirms the vaccine’s value and further underscores the ethical imperative not to deny newborns timely protection.

Media contact:
mediainquiries@who.int

You are receiving this NO-REPLY email because you are included on a WHO mail list.
If you have been forwarded this update you can click here to subscribe.
Journalists may send feedback to WHO Media Team

GAIN Reports from February 12, 2026

The following GAIN reports were released on February 12, 2026.

_______

China: Planting Seeds Annual 2025

China's seed supply for marketing year 2025/26 is sufficient to meet domestic demand, with seed producers generally achieving high yields for major crops including corn, rice, wheat, and soybeans. Imports of vegetable and grass seeds are declining due to rising domestic production, though China still relies on high-end foreign germplasm for specialty seeds. Seed exports are growing, particularly for rice, cotton, and vegetables, driven by strong demand in Asia for Chinese-developed seeds as a finished product for crop production as well as from foreign seed companies which utilize operations in China for certain intermediate portions of their global supply chains.

European Union: EU Early Alert - Pesticide Review - December 2025

The European Union (EU) follows a complex, rolling system of review for active ingredients and Maximum Residue Levels (MRLs) in food. For agricultural inputs, U.S. farmers must know early in the process of review to prevent or mitigate the loss of, and/or access to, chemical inputs. The information in this document provides interested stakeholders with advance notice of those active ingredients under review, highlighting those substances undergoing new restrictions or may not be renewed. This is a quarterly update from December 2025.

For more information, or for an archive of all FAS GAIN reports, please visit gain.fas.usda.gov/.

Update your subscriptions, modify your password or email address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your email address to log in. If you have questions or problems with the subscription service, please visit subscriberhelp.govdelivery.com.

This service is provided to you at no charge by USDA Foreign Agricultural Service.

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: USDA Foreign Agricultural Service · 1400 Independence Avenue, SW · Washington, DC 20250